ArticleScientific reports2026
SIRT1-mediated deacetylation of HMGB1 promotes the progression of endometriosis by regulating autophagy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis (EMs) is a disease characterized by the presence of endometrial tissue outside the uterus, which often causes pain, abnormal bleeding, and infertility. Sirtuin 1 (SIRT1)-mediated deacetylation is implicated in the progression of various diseases, yet its role in EMs remains unexplored. Normal, ectopic, and eutopic endometrial tissues from EMs or non-EMs patients were collected. RT-qPCR and Western blot analyses were performed to evaluate SIRT1 expression. Cell viability, migration, and invasion of human endometrial stromal cells (HESCs) were assessed using the MTT assay, Transwell migration, and invasion assays. Protein levels were analyzed via Western blot. The interaction between SIRT1 and high mobility group box 1 (HMGB1) was examined using co-immunoprecipitation. Finally, an EMs rat model was developed. Results demonstrated that both eutopic and ectopic endometrial tissues exhibited elevated SIRT1 expression. Furthermore, SIRT1 deficiency suppressed HESC viability, migration, invasion, and a phenotypic shift, as well as autophagy. Mechanistically, SIRT1 deficiency reduced HMGB1 protein stability in HESCs. Additionally, HMGB1 overexpression enhanced HESC viability, migration, invasion, autophagy, and induced a phenotypic switch characterized by downregulation of mesenchymal markers (e.g., vimentin, N-cadherin) and upregulation of the epithelial marker E-cadherin. In the rat model, SIRT1 silencing suppressed this phenotypic switch and autophagy in uterine tissue. Collectively, SIRT1-mediated deacetylation of HMGB1 at lysine 12 stabilized HMGB1 protein, promoting autophagy and enhancing the invasive and migratory capacity of HESCs, thus driving EMs progression—offering novel therapeutic insights for EMs treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.